| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.07 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.07 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.07 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.08 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.066 | 0.08 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.08 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.064 | 0.08 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.059 | 0.08 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.08 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.08 |